KCNA3 and head and neck squamous cell carcinoma: (78) demonstrated that treatment with both anti-PD1 (pembrolizumab) and anti-PD-L1 (atezolizumab) antibodies facilitated the function of KCa3.1 and Kv1.3 in head and neck squamous cell carcinoma (HNSCC) patients’ peripheral lymphocytes.